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Stress-related psychiatric disorders, such as unipolar depression and post-traumatic stress disorder (PTSD), occur
more frequently in women than in men. Emerging research suggests that sex differences in receptors for the stress
hormones, corticotropin releasing factor (CRF) and glucocorticoids, contribute to this disparity. For example, sex
differences in CRF receptor binding in the amygdala of rats may predispose females to greater anxiety following
stressful events. Additionally, sex differences in CRF receptor signaling and trafficking in the locus coeruleus arousal
center combine to make females more sensitive to low levels of CRF, and less adaptable to high levels. These
receptor differences in females could lead to hyperarousal, a dysregulated state associated with symptoms of
depression and PTSD. Similar to the sex differences observed in CRF receptors, sex differences in glucocorticoid
receptor (GR) function also appear to make females more susceptible to dysregulation after a stressful event.
Following hypothalamic pituitary adrenal axis activation, GRs are critical to the negative feedback process that
inhibits additional glucocorticoid release. Compared to males, female rats have fewer GRs and impaired GR
translocation following chronic adolescent stress, effects linked to slower glucocorticoid negative feedback. Thus,
under conditions of chronic stress, attenuated negative feedback in females would result in hypercortisolemia, an
endocrine state thought to cause depression. Together, these studies suggest that sex differences in stress-related
receptors shift females more easily into a dysregulated state of stress reactivity, linked to the development of mood
and anxiety disorders. The implications of these receptor sex differences for the development of novel
pharmacotherapies are also discussed.
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Many mood and anxiety disorders are considered stress-
related, because of the crucial role stress plays in their eti-
ology and symptomology. For example, stress is associated
with the onset and severity of unipolar depression, panic
disorder, and generalized anxiety disorder [1-7]. In the
case of post-traumatic stress disorder (PTSD), the disease
is, by definition, precipitated by a stressful event [4,8].
Additionally, early life stress can sensitize later responses
to stress and is associated with the development of mood
and anxiety disorders in adulthood [9-11].
A common feature shared by most stress-related psychi-
atric disorders is that they occur more frequently inCorrespondence: debra.bangasser@temple.edu
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reproduction in any medium, provided the orwomen than in men. Women are, in fact, twice as likely as
men to suffer from unipolar depression and several anx-
iety disorders, including PTSD [1,12-15]. This disparity is
often attributed to gender differences in psychological fac-
tors, including affect, cognitive style, and social role identi-
fication [16-23]. Some commonly presumed causes for the
gender gap, such as differences in the types of trauma
experienced, preexisting psychiatric disorders, and sex dif-
ferences in reporting, are unlikely to play a significant role
because the male–female disparity remains, even after
these variables have been controlled for [4,14,24,25].
Nonetheless, it is likely that some psychological factors
contribute to the sex bias in stress-related disease. New
research investigating molecular sex differences in stress
response systems, on the other hand, indicates that bio-
logical factors also contribute to sex differences in thed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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view will discuss emerging data that has identified sex
differences in receptors for the stress hormones, cortico-
tropin releasing factor (CRF) and glucocorticoids. The
reviewed studies suggest that receptor sex differences can
cause stress responses in females to shift more easily into
a dysregulated state and likely play an important role in
the disparity seen between males and females in mood
and anxiety rates.
Review
Endocrine and central effects of CRF
CRF is best known for its role in activating the hypothal-
amic pituitary adrenal (HPA) axis. This endocrine re-
sponse is initiated during a stressful event when CRF
released from neurons in the paraventricular nucleus of
the hypothalamus stimulates pituitary corticotropes to
secrete adrenocorticotropic hormone (ACTH) [26].
ACTH released into the bloodstream acts on the cortex
of the adrenal glands causing them to release glucocorti-
coids (cortisol in humans and corticosterone in rodents).
Glucocorticoids then feedback at the levels of the hypo-
thalamus and pituitary to terminate the HPA axis activa-
tion [27]. Additionally, these hormones act on the
hippocampus, which in turn provides negative feedback
to the hypothalamus in order to aid in the termination
of stress-induced activation of the HPA axis [28,29].
High levels of CRF immunoreactivity also are observed
outside of the hypothalamus in other forebrain regions,
such as the olfactory bulb, cerebral cortex, nucleus accum-
bens, septum, bed nucleus of the stria terminalis (BNST),
preoptic nuclei, amygdala, and hippocampus [30-32].
Mid- and hindbrain regions that contain CRF include the
periaqueductal gray, raphe nuclei, lateral tegmental nu-
cleus, locus coeruleus (LC), parabrachial nucleus, cerebel-
lum, and the nucleus of the solitary tract [30-32]. This
widespread extra-hypothalamic expression means that
CRF is in a position to centrally modulate a variety of cog-
nitive and behavioral responses to stress. For example,
CRF is known to activate the amygdala, BNST, and pre-
frontal cortex to mediate a number of behaviors, including
those related to anxiety, defensive responses, and fear con-
ditioning [31,33-39]. Additionally, monoaminergic neur-
onal transmission is regulated by CRF [40-43], further
underscoring the pivotal role of CRF in coordinating a
broad range of responses to stressful events.
CRF receptor distribution and function
CRF exerts its actions via two G-protein coupled recep-
tors: CRF1 receptor type (CRF1) and CRF2 receptor type
(CRF2) [44-46]. Both CRF receptors are found in regions
involved in regulating stress, mood, and anxiety. Specif-
ically, CRF1 is predominantly found in the cerebral cor-
tex, cerebellum, pons, and anterior lobe of the pituitary,while CRF2 is more prominent in the septum, choroid
plexus, and posterior lobe of the pituitary [47-49]. In
many brain regions, like the hypothalamus, hippocam-
pus, amygdala, and BNST, there is considerable variation
between the expression of CRF1 and CRF2 (e.g., CRF1
expression is greater in the periventricular zone of the
hypothalamus, while CRF2 expression is greater in the
ventromedial nucleus of the hypothalamus) [47-49]. This
heterogeneous distribution of CRF receptor subtypes
suggests that each subtype has a unique role in mediat-
ing CRF function. Genetic and pharmacological manipu-
lations support this idea. Activation of CRF1 initiates the
endocrine stress response and mediates anxiety-related
behavior, while CRF1 antagonism or receptor knockout
reduces anxiety [50-57]. The role of CRF2 in mediating
stress-related behavior is more complex. Data from CRF2
knockout mice suggest that activation CRF2 attenuates ac-
tivity of the HPA axis, thereby counteracting the stimulat-
ing effect of CRF1 [58-60]. The role of CRF2 in mediating
anxiety is less consistent with some, but not all, studies
implicating these receptors in the reduction of anxiety-
related behavior [50,59,61-64]. These inconsistencies
may arise from the fact that some effects of CRF2 are re-
gion specific [65-67]. Nevertheless, the sometimes oppos-
ing actions of CRF1 and CRF2 have led to proposal that
generally CRF1 increases while CRF2 decreases stress
responsivity [50].
Given the widespread distribution of CRF1 and CRF2,
it is clear that CRF is critically poised to modulate a
number of brain regions. Thus, it is not surprising that
dysregulation of CRF and its receptors can result in a
number of adverse consequences. CRF hypersecretion
is linked to the pathophysiology of depression and cer-
tain anxiety disorders [68-70]. High levels of CRF are
found in the cerebral spinal fluid and brain regions of
patients with depression and PTSD, and these levels are
reduced with antidepressant treatment [70-83]. Multiple
genomic studies have identified single nucleotide poly-
morphisms on the CRF1 gene that are linked to depres-
sion, panic disorder, and PTSD [84-89]. Further evidence
for CRF1 in mediating depression comes from a clinical
trial in which CRF1 antagonist treatment of depressed
patients reduced depressed mood and anxiety symptoms
[90]. Taken together, these studies suggest a causal role
for CRF dysregulation in the development of stress-
related pathology.
Sex differences in CRF receptors: Evidence from knockout
mice and binding studies
The psychiatric disorders linked to CRF dysregulation
occur more frequently in women. Thus, it is likely that sex
differences in the CRF system underlie this disparity. In-
deed, sex differences in CRF expression have been observed
in the paraventricular nucleus of the hypothalamus,
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CRF expression [91-94]. In addition to sex differences in
the expression of CRF, sex difference in CRF receptors
could contribute to sex differences in stress vulnerability.
Evidence for sex differences in CRF receptors comes, in
part, from CRF2 knockout mice that have a phenotype at-
tributable to unimpeded CRF1 activity [59,95]. Female
CRF2-deficint mice display more depressive-like behaviors
on the forced swim test than their male counterparts, an
effect blocked by a CRF1 receptor antagonist [95]. Not
only does this finding reveal that depressive-like behavior
is mediated, at least in part, by CRF1, but this result sug-
gests that sex differences at the level of the CRF1 contribute
to increased depressive-like behavior in females. Despite
this evidence for sex differences in CRF1, few studies have
directly evaluated sex differences in CRF receptor expres-
sion and function.
Recently, Weathington and Cooke (2012) identified
sex differences in CRF receptor binding in the amygdala.
CRF1 binding was significantly greater in the basolateral
and posteroventral nuclei of the amygdala in female than
male rats. Interestingly, this sex difference was not iden-
tified until after puberty. Sex differences in CRF2 binding
also emerged following puberty [96]. Compared to ju-
venile males, adult males had increased CRF2 binding in
the four subnuclei of the amygdala examined (i.e., baso-
lateral, posterodorsal, posteroventral, and central), while
CRF2 levels remained low following puberty in females.
Similarly, in the BNST, which is considered part of the
extended amygdala, adult male voles had greater CRF2
binding than their female counterparts [97]. Sex differ-
ences in CRF receptor binding in the amygdala could
contribute to sex differences in anxiety. Blocking or re-
ducing CRF1 receptors in the basolateral nucleus of the
amygdala decreases anxiety-related behavior [98,99]. If
the role of CRF2 in the amygdala is to counteract the
effects of CRF1 activation, like it is in other regions,
CRF2 activation could decrease CRF1-mediated anxiety.
Compared to males, female rats have a greater ratio of
CRF1:CRF2 binding in the basolateral nucleus of the
amygdala. This sex difference could translate into
increased anxiety following stressful events in females,
which, if true in humans, would predispose women anx-
iety disorders such as PTSD.
The fact that sex differences in CRF receptor binding
emerge after puberty, implicates the gonadal hormone
surges that occur during puberty in these effects [96].
Estrogen, androgen, and progesterone receptors are
found in CRF producing regions [49,100-104]. Moreover,
androgen treatment increases CRF2 mRNA in several
brain regions of male rats [105]. In the human myome-
trium, estrogen and progesterone increase CRF1 expres-
sion, although this has not yet been demonstrated in the
brain [106]. The mechanism underlying gonadal hormoneregulation of CRF receptor expression is not fully under-
stood, but putative estrogen, progesterone, and androgen
response elements have been identified on the promoter
regions of CRF receptor genes [105,107,108]. Thus, direct
regulation of gene transcription by gonadal hormones is
possible. Together these data suggest that sex difference
in CRF1 and CRF2 binding are likely due to gonadal hor-
mone regulation of CRF receptor number, rather than
other mechanisms (e.g., sex differences in differences in
receptor affinity for the CRF or neuronal number).
Sex differences in CRF1 receptor signaling
In addition to sex differences in CRF receptor binding, sex
differences in CRF1 signaling have been identified that
can render neurons of females more sensitive to CRF
[109-111]. The CRF1 is a G protein-coupled receptor that
changes conformation upon CRF binding to promote the
coupling of GTP binding proteins, which initiate intracel-
lular signaling cascades [51,112]. Although CRF1 can
promiscuously couple several G proteins, it preferentially
binds Gs [112,113]. CRF-induced Gs activation stimulates
adenylyl cyclase to form cyclic adenosine monophosphate
(cAMP), increasing protein kinase A (PKA) signaling
[114,115]. Sex differences in CRF1 coupling to Gs have
been identified [109]. Specifically, receptor immunopreci-
pitation of cortical tissue revealed that more Gs was pulled
down with the CRF1 of females compared to males under
unstressed conditions, indicating that the CRF1 in female
rat cortex is more highly coupled to Gs than in males.
Using the same immunoprecipitation technique, it was
found that acute stressor exposure (15 min of forced
swimming) enhanced CRF1-Gs coupling in males to
female levels. Stressed females had similarly high levels
of CRF1-Gs binding as unstressed females. Additionally,
these effects were not modulated by circulating ovarian
hormones as coupling was comparable in both ovariecto-
mized and intact female rats. The increased binding of
CRF1 to Gs in females would translate into greater cAMP-
PKA signaling in this group. Mice genetically modified to
have either greater Gs activation or increased PKA-
signaling have an anxiogenic phenotype [116,117]. Thus,
the sex difference in CRF1-Gs coupling and subsequent
signaling could increase anxiety in response to stressful
events in females.
Interestingly, sex differences in CRF1-Gs coupling may
also occur in other brain regions. Although the receptor
immunoprecipitation technique is limited to the cortex
because of the amount of protein required, the sex
difference in CRF1-Gs coupling found in cortex mirrors
the sex difference in the physiological response of LC
neurons to CRF. During a stressful event, CRF released
in the LC activates noradrenergic neurons to coordinate
arousal, attention, and vigilance [42,118-120]. LC neu-
rons of female rats are more sensitive to CRF than
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neuronal firing in males increases neuronal firing in
females [121]. Acute swim stress enhances LC neuronal
sensitivity in males to female levels, but does not alter
sensitivity of female neurons [121]. Notably, these sex
differences parallel the direction of the sex differences in
CRF1-Gs coupling in cortex, such that stressed males
and females (regardless of stress history) had neurons
that were more sensitive to CRF and CRF1 receptors that
were more highly coupled to Gs than unstressed males.
The CRF-induced increase in LC neuronal firing is
mediated by the cAMP-PKA signaling cascade [122].
Thus, the sex difference in coupling and subsequent sig-
naling likely causes the sex difference in LC physiology.
Consistent with this idea, pretreatment of LC neurons
with a cAMP antagonist revealed that the majority of
the LC physiological response to CRF in unstressed
females and stressed males was cAMP mediated,
whereas in unstressed males, only 50% of the LC re-
sponse to CRF was cAMP-mediated [109]. Together
these data suggest that sex differences in CRF1-Gs coup-
ling and cAMP-PKA signaling render LC neurons of
females more sensitive to CRF. This effect can have con-
sequences for LC-mediated stress responses in females.
Typically, activation of the LC-arousal system is thought
to be adaptive, as it promotes cognition and behavior
aimed at coping with stress [119,123]. However, activa-
tion of this system to stress levels by stimuli that should
be subthreshold for stress reactivity would be disruptive.
Given that female LC neurons are more sensitive to
CRF, LC activation is more likely to be inappropriately
elicited in females.
Sex differences in CRF1 receptor trafficking
Sex differences in CRF1 trafficking also are observed in LC
neurons. Like most G-protein coupled receptors, in re-
sponse to saturating concentrations of ligand, the CRF1 re-
ceptor is desensitized and internalized (i.e., trafficked from
the membrane to the cytosol) [51,124-126]. This is consid-
ered a cellular adaptation to high levels of CRF because the
internalized receptors can no longer be activated. Both
CRF agonist treatment and acute swim stress (15 min) in-
duce CRF1 internalization in LC neurons of male rats
[109,126,127]. Interestingly, swim stress fails to internalize
these receptors in female rats [109]. A failure of CRF1 in-
ternalization in females could result from sex differences in
CRF1 binding to β-arrestin, the protein that initiates the in-
ternalization process [51,128,129]. Stress increases CRF1-β-
arrestin binding in cortical tissue in males, but fails to do
so in females [109]. If the sex difference in CRF1 associ-
ation with β-arrestin is also present in LC neurons, it
would account for sex differences in CRF1 trafficking.
The lack of CRF1 internalization observed following
stress in females could result in female LC neurons thatare more sensitive to conditions of CRF hypersecretion,
which as noted, occurs in depression and PTSD. This idea
was tested by using CRF overexpressing mice that model
conditions of chronic stress and display anxiety-related be-
havior [130-132]. High levels of CRF expression in the LC
region were observed in CRF overexpressing mice, regard-
less of sex [133]. The firing rates of LC neurons were eval-
uated in these mice and compared to wild type controls.
LC firing rates were similar in male and female wild type
mice. However, LC neurons of female CRF overexpressing
mice fired roughly 3× faster than male and female wild
type controls [133]. Interestingly, the firing rates of male
overexpressing mice were maintained at wild type levels.
Because CRF expression was high in the LC of male over-
expressing mice, this result suggested the presence of some
compensatory cellular mechanism in this group. As noted,
internalization is a cellular adaptation that can reduce cel-
lular responding to high levels of CRF, so CRF1 internaliza-
tion was evaluated. Much like the trafficking pattern
following acute stress in rats, CRF1 receptors were interna-
lized in male but not female overexpressing mice [133].
The inability of female CRF1 to internalize under condi-
tions of CRF hypersecretion can explain the high LC neur-
onal firing rate in this group (Figure 1). High levels of LC
activation are linked to hyperarousal, a symptom of stress-
related disorders that leads to increased agitation, restless-
ness, re-experiencing, and sleep disturbance [69,134-136].
The aforementioned results suggest that sex differences
CRF1 modulation of the LC-arousal systems could more
easily shift females into this dysregulated state of
hyperarousal.
CRF binding protein (CRF-BP)
In addition to the mechanisms already discussed, the ac-
tivity of CRF is also regulated by CRF-BP [137-139]. CRF-
BP is expressed in the pituitary and in several brain
regions including the olfactory bulb, amygdala, BNST, the
ventral premammillary and dorsomedial nuclei of the
hypothalamus, and sensory relay nuclei in midbrain and
brain stem [140]. CRF-BP inhibits CRF-induced ACTH
release in pituitary corticotropes in vitro, suggesting CRF-
BP sequesters free CRF [141]. Centrally, both acute stress
and CRF administration increase the expression of CRF-
BP in the basolateral nucleus of the amygdala, an effect
that may facilitate recovery from stressor exposure [142-
144]. However, in the ventral tegmental area, CRF-BP
potentiates the signaling of CRF receptors, thereby ampli-
fying the effects of CRF [145]. Interestingly, sex differences
in expression of CRF-BP have been observed in the pituit-
ary, with female mice having higher levels of CRF-BP than
their male counterparts [146]. Thus, the complex role of
CRF-BP in modulating CRF, and its potential to contribute
to sex differences in the development of stress-related dis-
orders, certainly warrants further study.
Figure 1 This schematic illustrates sex differences in CRF1 trafficking in LC dendrites [133]. Under conditions of excessive release of CRF
(green), CRF1 receptors (blue) internalize in male neurons (left). This effect reduces neuronal responses to CRF in males. In females (right), CRF1
receptors fail to internalize under conditions of CRF hypersecretion, resulting in greater neuronal responses to CRF in this group.
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Activation of the HPA axis leads to the release of gluco-
corticoids. These stress hormones promote physiological
changes to adapt to acute stress, such as metabolizing
glucose, catabolizing proteins and lipids, and decreasing
inflammation [29]. As noted earlier, glucocorticoids also
feedback centrally and at the level of the pituitary to ter-
minate the endocrine response to stress. However, if the
HPA stress response becomes persistently activated due
to impaired negative feedback or other mechanisms,
then the adverse state of hypercortisolemia can occur.
Hypercortisolemia contributes to the pathophysiology of
a number of psychiatric and medical disorders including
depression [147-154].
Glucocorticoids act through two receptors: mineralo-
corticoid receptors (MRs) and glucocorticoid receptors
(GRs). MRs are highly expressed in the hippocampus
and septum, while GRs are found throughout the brain
in regions including the hippocampus, septum, amyg-
dala, hypothalamus, and the nucleus of the solitary tract
[155-157]. The affinity of these receptors is different,
such that glucocorticoids bind to MRs with higher affin-
ity (Kd, 1 nM), but to GRs with lower affinity (Kd, 2.5-5
nM) [155,156,158]. The differential distribution and af-
finity of these receptors has led to the proposal that
MRs maintain the tone of the stress system under nor-
mal conditions [155]. In contrast, GRs, because of their
lower affinity for the ligand, respond to high levels of
glucocorticoids to mediate the physiological recovery
from stressful events and restore the system to homeo-
stasis [155,159]. In support of this, there are two phases
of glucocorticoid negative feedback, fast and delayed,and both appear to be regulated by GRs. Specifically, fast
feedback is thought to be mediated by membrane bound
GRs that, when activated, induce endocannabinoid
suppression of the hypothalamus [160,161]. Delayed
feedback involves the translocation of nuclear GRs from
the cytosol to the nucleus where they can repress gene
transcription of CRF, CRF1, and precursors of ACTH
[162-167]. These studies highlight the fact that GRs are
the critical receptor subtype that coordinates the recov-
ery of the HPA axis response to stress.
Glucocorticoid negative feedback can be assessed by
the dexamethasone suppression test [168-171]. This test
was developed to diagnose Cushing’s syndrome, a dis-
order characterized by excessive endogenous gluco-
corticoid secretion, but also has been used to assess
HPA axis dysregulation in several psychiatric disorders,
including depression [168,169,171]. Dexamethasone is
a synthetic glucocorticoid that binds with high affinity
for GRs [172]. In normal subjects, dexamethasone sup-
presses the release of cortisol, but it fails to suppress
cortisol in 20-50% of depressed patients, indicating
impaired negative feedback [169-171]. When the dexa-
methasone suppression test is combined with the CRF
stimulation test, the sensitivity to differentiate between
normal and pathological states increases to 80%, suggest-
ing the combined test is a better assessment of the HPA
axis dysregulation observed in depression [173-175].
Decreased negative feedback in depression is thought to
result in the hypercortisolemia that is often observed
in these patients [147-153,176]. Interestingly, there is
evidence that HPA axis dysregulation precedes depres-
sion, and that cortisol levels and negative feedback
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covery [148,149,151]. Additionally, patients with Cush-
ing’s syndrome often experience depression, and
removal of their adrenal glands relieves depressive symp-
toms [177,178]. Taken together, these finding indicate
that changes in glucocorticoid negative feedback may
cause depressive symptoms [148,149,151].
Sex differences in glucocorticoid negative feedback
The most widely reported sex difference in stress response
systems is that female rodents have higher levels of HPA
axis hormones than males. Specifically, basal levels of glu-
cocorticoids are elevated in female rats relative to their
male counterparts [93,179,180]. Stressor exposure induces
greater corticosterone release for a longer duration in fe-
male than male rodents [91,93,179-185]. In contrast to the
consistent findings in rodents, reports of sex differences in
cortisol levels in humans are equivocal [186-196]. Despite
these discrepancies, mechanisms that can lead to higher
levels of glucocorticoids in females have been identified.
One such mechanism is greater CRF expression in the
hypothalamus of female compared to male rodents, which
can translate into greater HPA axis activation [91-94,197].
Another mechanism involves sex differences in gluco-
corticoid negative feedback. As noted, in response to acute
stress, female rodents have a protracted elevation of cor-
ticosterone, which is indicative of a slower negative feed-
back compared to males [91,180,184]. Studies in humans
also suggest that feedback is slower in women than men
[191-193]. Sex differences in negative feedback may be
established by ovarian hormones, because female rats trea-
ted with estrogen have a slower glucocorticoid feedback
than ovariectomized controls [198,199]. This suggests that
estrogen can decrease negative feedback, resulting in a
prolonged release of glucocorticoids in females.
Sex differences in glucocorticoid negative feedback may
be explained by sex differences in glucocorticoid receptor
number. In the pituitary, female rats have fewer MRs and
GRs than males [200]. Similarly, compared to male rats,
glucocorticoid binding is lower in the hypothalamus of
females, likely reflecting fewer receptors [201]. Estrogen
regulates the expression of receptors for glucocorticoids,
again highlighting the role of estrogen in establishing this
sex difference. Specifically, estrogen treatment decreased
GR mRNA in breast cancer cells [202]. Also, estrogen
treatment of ovariectomized females downregulated GR
expression in the hippocampus, hypothalamus, and pituit-
ary [200,203]. Thus, direct downregulation of glucocortic-
oid receptors by estrogen is possible.
Sex differences in GR translocation and other feedback
regulators
Another mechanism by which sex differences in gluco-
corticoid negative feedback can be established involvesGR translocation [204]. The process of translocation is
initiated by the binding of glucocorticoids to nuclear GRs.
The GRs then are shuttled by multiple co-chaperones
(e.g., PPID and FKBP52) into the nucleus to regulate gene
transcription [205-207]. In addition to co-chaperones
that promote GR translocation, other co-chaperones,
such as Bag1 and Fkbp5, inhibit GR translocation, high-
lighting that this process is highly regulated (Figure 2)
[205,207-210]. Bourke and colleagues (2012) identified
several co-chaperones that were regulated in a sex-specific
manner, and often these sex differences were exacerbated
by exposure to chronic stress. Alterations in co-chaperone
expression observed in female rats with a history of
chronic adolescent stress were linked to changes in gluco-
corticoid negative feedback [204]. Specifically, when these
females were exposed as adults to an acute stress chal-
lenge, elevated levels of Bag1 and Fkbp5 were observed.
Acute stressor exposure also attenuated GR translocation
and negative feedback in this group when compared to
females that were not stressed during adolescence. These
findings suggest that stress-induced increases in co-
chaperones that inhibit GR translocation result in
impaired glucocorticoid negative feedback in females.
Interestingly, a history of adolescent stress did not alter
GR translocation or HPA responses to acute stressor ex-
posure in males, indicating that females are more vulner-
able to stress during the adolescent period.
Sex differences in glucocorticoid negative feedback
may also occur via mechanisms other than GR expres-
sion and translocation. Progesterone can compete with
glucocorticoids for binding cites on GR itself, while es-
trogen receptors can compete with GRs for a binding
site on the promoter region of genes, demonstrating that
ovarian hormones can directly block glucocorticoid
actions [211,212]. Additionally, because estrogen recep-
tors co-localize with GABA neurons in the area around
the paraventricular of the hypothalamus nucleus, it has
been proposed that estrogen can reduce GABA input
into the hypothalamus, thereby indirectly inhibiting
negative feedback in females [213]. Together these stud-
ies suggest that the regulation of glucocorticoid negative
feedback by ovarian hormones is complex and not lim-
ited to effects solely at GR regulation. Nevertheless, the
reduction in GR levels and the prevention of their trans-
location into the nucleus in stressed females would de-
crease the ability of glucocorticoids to repress CRF and
ACTH gene transcription. Thus, sex differences at the
level of GRs are likely important mechanisms that lead
to increased stress hormones levels in women. Under
typical conditions, slight increases in glucocorticoid
levels due to a protracted negative feedback may not im-
pact women. However, under conditions of chronic
stress, the slower termination of the HPA axis response
in women could result in high glucocorticoid levels for
Figure 2 This schematic depicts the role of GR translocation in glucocorticoid negative feedback. Glucocorticoids readily cross the plasma
membrane to bind nuclear GRs. GRs then are shuttled into the nucleus by multiple co-chaperones (in green), such as PPID and FKBP52. Once
inside, GRs bind to glucocorticoid response elements (GREs) on genes to repress transcription of CRF and precursors for ACTH. Other co-
chaperones (in red), including Bag1 and Fkbp5, inhibit GR translocation, an effect which can attenuate negative feedback.
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thought to cause depression, sex differences in gluco-
corticoid negative feedback may predispose women to
this disease [148,149,151].
Implications for pharmacotherapy
The aforementioned studies reveal sex differences at the
level of two receptors that mediate responses to stress:
CRF1 and GR. Not only can these sex differences con-
tribute to the development of mood and anxiety disor-
ders, but they have implications for pharmaceutical
treatments. For example, CRF1 antagonists are currently
being developed to treat stress-related disorders [214-216].
The fact that the CRF1 binds Gs and β-arrestin proteins
differently in males versus females suggests sex differ-
ences in the conformation of this receptor. This con-
formational change could alter the binding of CRF1
antagonists, changing their efficacy in men versus
women. Understanding the mechanisms that differen-
tially regulate these receptors in males and females may
also lead to novel treatments. Perhaps future pharma-
cotherapies could be developed to promote β-arrestin
binding to CRF1, thereby stimulating internalization, a
potentially longer lasting treatment than could be
achieved with CRF1 antagonists. Other compounds tar-
geting co-chaperones to increase GR translocationcould accelerate negative feedback of the HPA re-
sponse. Given the sex differences in CRF1internaliza-
tion and GR translocation, both of these treatments are
likely to be particularly effective in women.
These studies also underscore the importance of using
female subjects in preclinical research. A review of the
non-human animal studies published in 2009 found that
single-sex studies of male animals outnumbered those of
females 5.5 to 1 in neuroscience and 5 to 1 in pharma-
cology [217]. Given the evidence that sex differences
occur at the receptor level, it is possible that receptor
antagonists would work well in one sex but not the
other. In fact, one interesting possibility is that the
pharmacological treatments discussed above may only
be effective for the treatment of stress-related disorders
in females. Because compounds are typically screened
exclusively in male animals, new drugs that appear to be
ineffective for males would never get past the preclinical
drug development stage, despite the fact that they may
be very effective for females. This scenario could deny
women with mood and anxiety disorders important
treatment options.
Conclusions
The emerging literature on sex differences in stress-
related receptors indicates that, although psychological
Bangasser Biology of Sex Differences 2013, 4:2 Page 8 of 13
http://www.bsd-journal.com/content/4/1/2factors may play a role, biological factors also contribute
to sex differences in stress-related psychiatric disorders.
Moreover, these studies are not only advancing our
understanding of the neurobiological bases for this sex
bias, but they also may guide the development of novel
pharamotherapies. In addition, the fact that sex differ-
ences occur at the receptor level has even broader impli-
cations. These are the first reports, to my knowledge, of
sex differences in G-protein coupled receptor signaling
and steroid hormone receptor translocation. It is pos-
sible that similar sex differences occur in other G-
protein coupled and steroid hormone receptors. If sup-
ported by future studies, sex differences in receptor
function may also explain why many other psychiatric
disorders (e.g., autism, attention-deficit disorder, etc.)
occur at different rates in men and women [218,219].
Thus, sex differences at the receptor level may be an im-
portant yet underexplored determinant of vulnerability
to a wide range of psychiatric diseases.
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